Next Article in Journal
TRIM8: Making the Right Decision between the Oncogene and Tumour Suppressor Role
Previous Article in Journal
Circular RNAs (circRNAs) in Health and Disease
Previous Article in Special Issue
The Plasticizer Bisphenol A Perturbs the Hepatic Epigenome: A Systems Level Analysis of the miRNome
Article Menu

Export Article

Open AccessReview
Genes 2017, 8(12), 349; doi:10.3390/genes8120349

The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines

1
Zoology, Genetics and Physical Anthropology Department Veterinary Faculty, Universidade de Santiago de Compostela, Lugo 27002, Spain
2
Nano-Oncology Unit, Translational Medical Oncology Group, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela (CHUS), CIBERONC, Santiago de Compostela 15706, Spain
3
Geneaqua S.L., Lugo 27002, Spain
These authors contributed equally to this work.
*
Author to whom correspondence should be addressed.
Academic Editor: Paolo Cinelli
Received: 9 October 2017 / Revised: 6 November 2017 / Accepted: 21 November 2017 / Published: 28 November 2017
(This article belongs to the Special Issue Zebrafish: The Key for Cancer Treatment)
View Full-Text   |   Download PDF [1043 KB, uploaded 1 December 2017]   |  

Abstract

In the last few decades, the field of nanomedicine applied to cancer has revolutionized cancer treatment: several nanoformulations have already reached the market and are routinely being used in the clinical practice. In the case of genetic nanomedicines, i.e., designed to deliver gene therapies to cancer cells for therapeutic purposes, advances have been less impressive. This is because of the many barriers that limit the access of the therapeutic nucleic acids to their target site, and the lack of models that would allow for an improvement in the understanding of how nanocarriers can be tailored to overcome them. Zebrafish has important advantages as a model species for the study of anticancer therapies, and have a lot to offer regarding the rational development of efficient delivery of genetic nanomedicines, and hence increasing the chances of their successful translation. This review aims to provide an overview of the recent advances in the development of genetic anticancer nanomedicines, and of the zebrafish models that stand as promising tools to shed light on their mechanisms of action and overall potential in oncology. View Full-Text
Keywords: nanomedicines; cancer; gene therapies; zebrafish; translation nanomedicines; cancer; gene therapies; zebrafish; translation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Gutiérrez-Lovera, C.; Vázquez-Ríos, A.; Guerra-Varela, J.; Sánchez, L.; de la Fuente, M. The Potential of Zebrafish as a Model Organism for Improving the Translation of Genetic Anticancer Nanomedicines. Genes 2017, 8, 349.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Genes EISSN 2073-4425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top